- cafead Jan 07, 2020 at 11:22: PM
via Clovis Oncology (NASDAQ:CLVS) reported $38.3 million to $39.3 million in preliminary fourth quarter sales of its cancer drug Rubraca. At the midpoint, that's 27.6% higher than the year-ago quarter, but only a 3.2% increase compared to the third quarter. For the full year, preliminary Rubraca sales were in the $142 million to $143 million range, almost a 50% increase over 2018.
article source
article source